Intercept Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INTERCEPT PHARMS INC, and what generic alternatives to INTERCEPT PHARMS INC drugs are available?
INTERCEPT PHARMS INC has one approved drug.
There are seven US patents protecting INTERCEPT PHARMS INC drugs.
There are one hundred and eighteen patent family members on INTERCEPT PHARMS INC drugs in thirty-seven countries and twelve supplementary protection certificates in eleven countries.
Summary for Intercept Pharms Inc
International Patents: | 118 |
US Patents: | 7 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Intercept Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 10,174,073 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 10,758,549 | ⤷ Sign Up | ⤷ Sign Up | ||||
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | 10,052,337 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 10,047,117 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Intercept Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | 7,138,390 | ⤷ Sign Up |
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | 8,377,916 | ⤷ Sign Up |
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | 8,058,267 | ⤷ Sign Up |
Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | 8,377,916 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Intercept Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2440680 | ⤷ Sign Up |
Australia | 2020202405 | ⤷ Sign Up |
Singapore | 11201408501U | ⤷ Sign Up |
Israel | 257841 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Intercept Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1392714 | 132017000061826 | Italy | ⤷ Sign Up | PRODUCT NAME: ACIDO OBETICOLICO(OCALIVA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1139, 20161215 |
1392714 | 2017/019 | Ireland | ⤷ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REGISTRATION NO/DATE: EU/1/16/1139/001 EU/1/16/1139/002 20161212 |
1392714 | 1790020-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
1392714 | 17C0003 | France | ⤷ Sign Up | PRODUCT NAME: ACIDE OBETICHOLIQUE; REGISTRATION NO/DATE: EU/1/16/1139 20161212 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.